Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Yoshinobu Nakamaru"'
Autor:
Takahiro Oguma, Chiaki Kuriyama, Keiko Nakayama, Yasuaki Matsushita, Kumiko Yoshida, Satoko Kiuchi, Yuka Ikenaga, Yoshinobu Nakamaru, Kumiko Hikida, Akira Saito, Kenji Arakawa, Kozo Oka, Kiichiro Ueta, Masaharu Shiotani
Publikováno v:
Journal of Pharmacological Sciences, Vol 127, Iss 4, Pp 456-461 (2015)
To assess the impact of concomitant inhibition of sodium-glucose cotransporter (SGLT) 2 and dipeptidyl peptidase IV (DPP4) for the treatment of type 2 diabetes mellitus (T2DM), the effect of combined treatment with canagliflozin, a novel SGLT2 inhibi
Externí odkaz:
https://doaj.org/article/a6e709c959c5400b8377221d633d3134
Autor:
Kazuoki Kondo, Yukiko Nishimura, Yuichiro Kato, Yoshinobu Nakamaru, Hidetoshi Shimizu, Hideaki Matsuda, Yoichi Shiide, Makoto Akimoto, Munetomo Matsuda
Publikováno v:
Clinical Pharmacology in Drug Development
Intravenous (IV) edaravone is approved as an amyotrophic lateral sclerosis (ALS) treatment. Because IV administration places a burden on patients, development of orally administered ALS treatments is needed. Therefore, 2 phase 1 studies of oral formu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3e7b2ae163a134ef269f3c843a032d8
http://europepmc.org/articles/PMC8518673
http://europepmc.org/articles/PMC8518673
Publikováno v:
Clinical Therapeutics. 42:1699-1714
Purpose The goal of this study was to compare edaravone pharmacokinetic (PK) variables and tolerability after a single intravenous (IV) infusion of 30 mg over 60 min in subjects with mild renal impairment (estimated glomerular filtration rate 60–89
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::392c20c538f17e9061b1eb1fbeab50cc
https://doi.org/10.1016/j.clinthera.2020.06.020
https://doi.org/10.1016/j.clinthera.2020.06.020
Autor:
Hidetoshi Shimizu, Kaori Yoshida, Makoto Akimoto, Tomoko Natori, Shinsuke Inoue, Mai Endo, Kazuoki Kondo, Masae Kakubari, Yoshinobu Nakamaru
Publikováno v:
Clinical Pharmacology in Drug Development
This randomized, single‐blind, 3‐way crossover study assessed the effect of edaravone on QT interval, including an exposure‐response analysis. Twenty‐seven healthy Japanese male volunteers, aged 20 to 49 years, were randomly assigned to recei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1a6e283b824a7c5c6d89a23f04c3041
https://doi.org/10.1002/cpdd.814
https://doi.org/10.1002/cpdd.814
Autor:
Yoshinobu Nakamaru, Kazumi Mori-Anai, Takayuki Takahata, Ryuta Saito, Yoshihiko Tashima, Tomohisa Nakada
Publikováno v:
Biopharmaceuticsdrug dispositionREFERENCES. 41(8-9)
Sodium-dependent glucose transporter (SGLT) 2 is specifically expressed in the kidney, while SGLT1 is present in the kidneys and small intestine. SGLT2 inhibitors are a class of oral antidiabetic drugs that lower elevated plasma glucose levels by pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b299f7bba338e6828b660ef5300dd7c6
https://pubmed.ncbi.nlm.nih.gov/33085977
https://pubmed.ncbi.nlm.nih.gov/33085977
Autor:
Atsuhiro Kawaguchi, Yoshinobu Nakamaru, Shuji Kinoshita, Joseph Palumbo, Koji Takei, Masayuki Suzuki
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 18:80-87
Amyotrophic lateral sclerosis (ALS) affects persons of all races, and there continues to be a need for effective therapies to treat the disease.To compare the pharmacokinetics (PK) of edaravone between Japanese and Caucasian populations.Data from fiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d8d7b46699202e018508865ed88eb6
https://doi.org/10.1080/21678421.2017.1353100
https://doi.org/10.1080/21678421.2017.1353100
Publikováno v:
Biopharmaceutics & Drug Disposition. 37:491-506
Canagliflozin is a recently developed sodium-glucose cotransporter (SGLT) 2 inhibitor that promotes renal glucose excretion and is considered to inhibit renal SGLT2 from the luminal side of proximal tubules. Canagliflozin reportedly inhibits SGLT1 we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a0c9702860813ee9b9a17143954e4e1
https://doi.org/10.1002/bdd.2040
https://doi.org/10.1002/bdd.2040
Autor:
Yoshinobu Nakamaru, Akihito Ogasawara, Tomohisa Nakada, Koki Kojima, Hiroshi Yamazaki, Hidetoshi Shimizu, Kosuke Yoshida
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 47(2)
Predicting the pharmacokinetics of compounds in humans is an important part of the drug development process. In this study, the plasma concentration profiles of 10 marketed compounds exhibiting two-phase elimination after intravenous administration i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7450a98e524d761c243ac3d5410575f7
https://pubmed.ncbi.nlm.nih.gov/30420404
https://pubmed.ncbi.nlm.nih.gov/30420404
Publikováno v:
Biopharmaceutics & Drug Disposition. 36:148-162
Teneligliptin is a type 2 diabetes drug that has an inhibitory effect on dipeptidyl peptidase-4. The aim of this study was to establish a physiologically based pharmacokinetic (PBPK) model to elucidate in detail the pharmacokinetics of teneligliptin.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::790e46828b754ad925129d6f5f661a86
https://doi.org/10.1002/bdd.1928
https://doi.org/10.1002/bdd.1928
Autor:
Atsuhiro Kawaguchi, Martin Davies, Yoshinobu Nakamaru, Shuji Kinoshita, Kei Akimoto, Hiroshi Yamazaki, Horst Jürgen Heuer, Yoshiharu Hayashi, Mana Sekine, Jeff Thompson
Publikováno v:
Clinical Therapeutics. 36:760-769
Objective The aim of this study was to examine the effect of ketoconazole, a potent cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp) inhibitor, on teneligliptin pharmacokinetics and to evaluate the safety of combined administration of teneliglipti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec7261d5ab657be5962357e4fc24037c
https://doi.org/10.1016/j.clinthera.2014.03.002
https://doi.org/10.1016/j.clinthera.2014.03.002